MeSH Browser

MeSH Heading: Baclofen
Tree Number(s): D02.241.081.114.500.350.100
Unique ID: D001418
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D001418
Scope Note: A GAMMA-AMINOBUTYRIC ACID derivative that is a specific agonist of GABA-B RECEPTORS. It is used in the treatment of MUSCLE SPASTICITY, especially that due to SPINAL CORD INJURIES. Its therapeutic effects result from actions at spinal and supraspinal sites, generally the reduction of excitatory transmission.
Entry Term(s): Apo-Baclofen; Atrofen; Ba-34,647; Ba-34647; Baclofen AWD; Baclofène-Irex; Baclophen; Baclospas; CIBA-34,647-BA; Chlorophenyl GABA; Clofen; Gen-Baclofen; Genpharm; Lebic; Lioresal; Liorésal; Nu-Baclo; PCP-GABA; PMS-Baclofen; beta-(Aminomethyl)-4-chlorobenzenepropanoic Acid; beta-(p-Chlorophenyl)-gamma-aminobutyric Acid
Pharm Action: Muscle Relaxants, Central
GABA-B Receptor Agonists
Registry Numbers: H789N3FKE8; 0
Related Numbers: 1134-47-0
CAS Type 1 Name: Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-
NLM Classification #: QV 140
Previous Indexing: Aminobutyric Acids (1972-1974); Chlorobenzenes (1974)
Public MeSH Note: 80; was see under AMINOBUTYRIC ACIDS 1975-79
History Note: 80(75); was see under AMINOBUTYRIC ACIDS 1975-79
Date Established: 1980/01/01
Date of Entry: 1974/11/11
Revision Date: 2016/07/05

Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

agonists (AG)

analogs & derivatives (AA)

analysis (AN)

antagonists & inhibitors (AI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

economics (EC)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

urine (UR)

Concept UI: M0002117
Registry Numbers: H789N3FKE8
Related Numbers: 1134-47-0
Scope Note: A GAMMA-AMINOBUTYRIC ACID derivative that is a specific agonist of GABA-B RECEPTORS. It is used in the treatment of MUSCLE SPASTICITY, especially that due to SPINAL CORD INJURIES. Its therapeutic effects result from actions at spinal and supraspinal sites, generally the reduction of excitatory transmission.
Terms: Baclofen Preferred Term
Term UI T004124
Date01/01/1999
LexicalTag NON
ThesaurusID; Chlorophenyl GABA
Term UI T004125
Date02/23/1979
LexicalTag NON
ThesaurusID UNK (19XX); beta-(p-Chlorophenyl)-gamma-aminobutyric Acid
Term UI T004127
Date10/22/1990
LexicalTag NON
ThesaurusID NLM (1992); PCP-GABA
Term UI T004128
Date10/22/1990
LexicalTag ABB
ThesaurusID NLM (1992); beta-(Aminomethyl)-4-chlorobenzenepropanoic Acid
Term UI T004130
Date09/02/1993
LexicalTag NON
ThesaurusID NLM (1995); Baclophen
Term UI T004131
Date02/23/1979
LexicalTag NON
ThesaurusID UNK (19XX)

Baclofen MeSH Descriptor Data 2024